228.03 USD
-2.69
1.17%
At close Jul 11, 4:00 PM EDT
After hours
228.03
+0.00
0.00%
1 day
-1.17%
5 days
-4.01%
1 month
-5.28%
3 months
3.14%
6 months
9.96%
Year to date
12.63%
1 year
4.68%
5 years
51.86%
10 years
238.17%
 

About: Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Employees: 17,787

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

40% more first-time investments, than exits

New positions opened: 95 | Existing positions closed: 68

10% more capital invested

Capital invested by funds: $18.8B [Q4 2024] → $20.7B (+$1.91B) [Q1 2025]

1% more funds holding

Funds holding: 756 [Q4 2024] → 764 (+8) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 290 | Existing positions reduced: 278

0.53% more ownership

Funds ownership: 92.86% [Q4 2024] → 93.39% (+0.53%) [Q1 2025]

9% less call options, than puts

Call options by funds: $8.15M | Put options by funds: $8.91M

43% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 4 (-3) [Q1 2025]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$250
10%
upside
Avg. target
$263
15%
upside
High target
$280
23%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
Jefferies
David Windley
15%upside
$263
Hold
Initiated
29 May 2025
Morgan Stanley
Patrick Wood
14%upside
$260
Equal-Weight
Maintained
19 May 2025
JMP Securities
David Turkaly
23%upside
$280
Market Outperform
Maintained
16 May 2025
Stephens & Co.
Steven Etoch
10%upside
$250
Overweight
Reiterated
15 May 2025

Financial journalist opinion

Based on 3 articles about STE published over the past 30 days

Negative
Zacks Investment Research
1 day ago
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
Positive
The Motley Fool
1 week ago
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money.
Investing in growth stocks is a proven way to increase your investment portfolio over the long term. By parking available funds, say $5,000, in strong, growing companies, and keeping it there long-term, you are likely to see the value of those investments rise steadily, generating the funds you need to finance your future lifestyle.
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money.
Negative
Zacks Investment Research
4 weeks ago
Why Is Steris (STE) Down 1.8% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Why Is Steris (STE) Down 1.8% Since Last Earnings Report?
Positive
Zacks Investment Research
1 month ago
AST Business Growth & Strategic Acquisitions Support STERIS Stock
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
AST Business Growth & Strategic Acquisitions Support STERIS Stock
Positive
Zacks Investment Research
1 month ago
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
Neutral
GlobeNewsWire
1 month ago
U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report 2025-2030 Featuring STERIS, The Brewer Company, Midmark Corp. (Ritter Midmark), Clinton Industries, UMF Medical and More
Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report by Product (Gynecological Chairs, Gynecological Tables), Application (Urology Surgery, Pelvic Surgery), End-use, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The U.S. Gynecological Chairs and Tables Market was valued at USD 194.8 Million in 2024, and is projected to reach USD 283.8 Million by 2030, rising at a CAGR of 6.50%.
U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report 2025-2030 Featuring STERIS, The Brewer Company, Midmark Corp. (Ritter Midmark), Clinton Industries, UMF Medical and More
Neutral
Zacks Investment Research
1 month ago
Deciphering Steris (STE) International Revenue Trends
Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Deciphering Steris (STE) International Revenue Trends
Positive
Seeking Alpha
1 month ago
Steris: May Benefit From Bringing Pharmaceutical Manufacturing Back To The U.S.
Steris plc remains a Strong Buy with a fair value of $281, supported by robust organic growth and margin expansion. The Trump administration's push to reshore pharma manufacturing could be a major tailwind for Steris's AST business. Steris's balanced growth in pricing and volume, along with cost initiatives, positions it for continued operating margin improvement.
Steris: May Benefit From Bringing Pharmaceutical Manufacturing Back To The U.S.
Neutral
Seeking Alpha
1 month ago
STERIS plc (STE) Q4 2025 Earnings Call Transcript
STERIS plc (NYSE:STE ) Q4 2025 Results Conference Call May 15, 2025 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President and Chief Financial Officer Dan Carestio - President and Chief Executive Officer Conference Call Participants Dave Turkaly - Citizens Mike Matson - Needham & Company Patrick Wood - Morgan Stanley Mac Etoch - Stephens, Inc Michael Polark - Wolfe Research Jason Bednar - Piper Sandler Brett Fishbin - KeyBanc Operator Good morning, everyone, and welcome to the STERIS plc Fourth Quarter 2025 Conference Call. All participants will be in a listen-only mode.
STERIS plc (STE) Q4 2025 Earnings Call Transcript
Positive
Barrons
1 month ago
Why This Medical Equipment Stock Is Today's S&P 500 Winner
Steris beat quarter.y earnings and revenue expectations and got a price target boost from Morgan Stanley.
Why This Medical Equipment Stock Is Today's S&P 500 Winner
Charts implemented using Lightweight Charts™